Five of the best-known contract sales providers have changed owners, leaders, or reporting structure since 2022. Contracts should reflect those changes, writes Hoyt Gong.

On this weeks episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s.

On this weeks episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...

In pharma, an oncology drug approval is a significant milestone. I have spent enough time in this space to know that it is also the moment where a different, less visible problem begins. The community ...

Most breakthrough medicines begin in academia, are developed further in biotechnology companies and, if successful, eventually end up in the hands of large pharmaceutical companies capable of bringing ...

For decades, the Silicon Valley playbook has dominated the narrative of innovation: a brilliant founder hacks together a minimum viable product in a garage, pitches a traditional venture capital (VC) ...

Life sciences companies operate at the leading edge of innovation, structuring high-value licensing, development, and outsourcing arrangements in a highly regulated environment. A persistent and often ...

"The pioneer spirit is still vigorous within this nation. Science offers a largely unexplored hinterland for the pioneer who has the tools for his task. Scientific progress is one essential key to our ...

In the United States, it has typically taken 10 to 15 years for breakthrough research to be adopted in real-world clinical settings: a decade or more between proving something saves lives and actually ...

Bouncing around the San Diego Convention Center’s 2.6 million square feet for four days is its own kind of flustery exercise, but in the age of Zoom it’s a more-than-welcome excursion. It’s hard to ...

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.